Non-steroidal anti-inflammatory drug use and risk of venous thromboembolism

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 7, 2011, Pages 1326-1333

  Schmidt, M ^a   Christiansen, C F ^a   Horvath Puho E ^a   Glynn, R J ^b   Rothman, K J ^c   Sorensen H T ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c RTI HEALTH SOLUTIONS   (United States)

Author keywords

Cardiovascular disease; Case control study; Cyclooxygenase 2 inhibitors; Epidemiology; Non steroidal anti inflammatory drugs; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DEXIBUPROFEN; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETODOLAC; ETORICOXIB; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NABUMETONE; NAPROXEN; NEUROLEPTIC AGENT; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PARECOXIB; PIROXICAM; ROFECOXIB; TOLFENAMIC ACID; UNINDEXED DRUG; VALDECOXIB;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DRUG USE; FEMALE; HORMONAL THERAPY; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DENMARK; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; REGISTRIES; RISK; VENOUS THROMBOEMBOLISM;

EID: 79959817996     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04354.x     Document Type: Article

References (24)

1. Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum 2002; 32: 25-32.
2. Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat 2007; 82: 85-94.
3. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Metaanalysis of randomised trials. BMJ 2006; 332: 1302-8.
4. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002; 162: 1182-9.
5. Huerta C, Johansson S, Wallander MA, García Rodríguez LA. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007; 167: 935-43.
6. Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Haemost 2006; 21: 23-9.
7. Goldhaber SZ. Pulmonary embolism. Lancet 2004; 363: 1295-305.
8. Kyrle PA, Eichinger S. Deep vein thrombosis. Lancet 2005; 365: 1163-74.
9. Danish Medicines Agency.. Accessed 20 January 2011.
10. Pedersen CB, Gøtzsche H, Møller JO, Mortensen PB. The Danish Civil Registration System. A cohort of eight million persons. Dan Med Bull 2006; 53: 441-9.
11. Andersen TF, Madsen M, Jorgensen J, Mellemkjaer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46: 263-8.
12. Glynn RJ, Rosner B. Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism. Am J Epidemiol 2005; 162: 975-82.
13. Gaist D, Sorensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997; 44: 445-8.
14. Thomsen RW, Riis A, Munk EM, Norgaard M, Christensen S, Sorensen HT. 30-day mortality after peptic ulcer perforation among users of newer selective COX-2 inhibitors and traditional NSAIDs: a population-based study. Am J Gastroenterol 2006; 101: 2704-10.
15. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-20.
16. Horwitz RI, Feinstein AR. The problem of 'protopathic bias' in case-control studies. Am J Med 1980; 68: 255-8.
17. Rothman KJ, Greenland S, Lash TL. Case-control studies. In: Rothman KJ, Greenland S, Lash TL, eds. Modern Epidemiology, 3rd edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2008: 124-5.
18. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006; 15: 291-303.
19. Chan AL. Celecoxib-induced deep vein thrombosis. Ann Pharmacother 2005; 39: 1138.
20. Westgate EJ, FitzGerald GA. Pulmonary embolism in a woman taking oral contraceptives and valdecoxib. PLoS Med 2005; 2: e197.
21. Nagai N, Hoylaerts MF, Gallacher DJ, Lu HR, Lijnen HR. Prothrombotic effect of Rofecoxib in a murine venous thrombosis model. Thromb Res 2008; 122: 668-73.
22. Prandoni P. Venous and arterial thrombosis: two aspects of the same disease? Clin Epidemiol 2009; 1: 1-6.
23. Sørensen HT, Horvath-Puho E, Pedersen L, Baron JA, Prandoni P. Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 2007; 370: 1773-9.
24. Severinsen MT, Kristensen SR, Overvad K, Dethlefsen C, Tjønneland A, Johnsen SP. Venous thromboembolism discharge diagnoses in the Danish National Patient Registry should be used with caution. J Clin Epidemiol 2010; 63: 223-8.